Business EconomyPosted at: Nov 5 2025 7:11PM


Sun Pharma Q2FY26 net profit rises 2.5pc to Rs 3,118 cr

Mumbai, Nov 5 (UNI) Sun Pharmaceutical Industries officially announced here on Wednesday that it has reported a consolidated net profit of Rs 3,117.95 crore in the second quarter of FY26, registering a growth of 2.55pc from Rs 3,040.16 crore in the year-ago period.
According to an official statement, the company's total revenue from operations in Q2FY26 increased by almost 9pc to Rs 14,478.31 crore from Rs 13,291.39 crore, on an year-on-year (YoY) basis.
Sun Pharma reported an EBITDA of Rs 4,527.1 crore during the September quarter, recording a 14.9pc YoY growth, with an EBITDA margin of 31.3pc.
Sun Pharmaceutical Industries Managing Director Kirti Ganorkar said, "India, emerging markets and the rest of the world led our growth for the period. US sales of innovative medicines surpassed generics for the first time during the quarter".
During the quarter, four Abbreviated New Drug Applications (ANDAs) were filed, while approval was received for 5 ANDAs. Sun's portfolio includes 57 approved NDAs while 14 NDAs await US FDA approval. One NDA was filed during the quarter, according to the company's official statement.
Formulation sales in India were at Rs 4,734.8 crore, registering a growth of 11pc. India Formulation sales accounted for 32.9pc of total consolidated sales for the quarter. The company launched 9 new products during the quarter and 15 products to date.
Formulation sales in Rest of World (RoW) markets were USD 234 million for Q2FY26, are up by 17.7pc and accounted for 14.2pc of total consolidated sales for the quarter. For the first half, sales were USD 453 million, up by 16.6pc over same period last year.
Emerging Markets formulations sales increased by 10.9pc to USD 325 million for Q2FY26 and accounted for 19.7pc of total consolidated sales. Formulation sales in Rest of World (RoW) markets were USD234 million during the quarter, up by 17.7pc and accounted for 14.2pc of total consolidated sales for the quarter.
Global Innovative Medicines sales were USD 333 million for Q2FY26, up 16.4pc over Q2 last year and accounted for 20.2pc of total consolidated sales for the quarter. For the first half, sales were USD 644 million, up by 16.6pc over the same period last year. During the quarter, Leqselvi was launched in the US for the treatment of severe alopecia areata.
For Q2FY26, external sales of Active Pharmaceutical Ingredients (APIs) were Rs 4,299 million, down by 19.5pc. For the first half, API sales were Rs 9,702 million, a decline of 5.7pc over the same period last year.
UNI BA SAS
Please log in to get detailed story.
Tags: #Sun Pharma Q2FY26 net profit rises 2.5pc to Rs 3#118 cr
More News

Rising cost of education & superior returns boost investors interest in children’s mutual funds: ICRA Analytics

15 Dec 2025 | 3:51 PM

Kolkata, Dec 15 (UNI) Children’s mutual fund, which has clocked an impressive CAGR growth of around 21.08 per cent over the last five years, is expected to register a double-digit growth in the coming years. Rising cost of education, which has been increasing by 11–12 per cent annually, and the superior returns generated by these funds are driving parents toward market-linked instruments for long-term planning, ICRA Analytics said.

see more..

Wheels India signs technical agreement with Japan’s Topy industries

15 Dec 2025 | 1:48 PM

Chennai, Dec 15 (UNI) Wheels India has signed a Technical Assistance Agreement with Tokyo,
Japan headquartered Topy Industries for the design, development and manufacture of aluminium alloy
wheels.

see more..

KPMG report says EV sales in India could reach 22 million units by 2035

15 Dec 2025 | 1:41 PM

Kolkata, Dec 15 (UNI) India’s electric vehicle (EV) journey has evolved from cautious early adoption to rapid acceleration, driven by strong government support, favorable economics, rapid infrastructure development, technological progress, and changing consumer preferences.

see more..

Sagar Defence to establish India’s 1st autonomous maritime shipyard in AP

14 Dec 2025 | 9:30 PM

Vijayawada, Dec 14 (UNI) In a major milestone for India’s maritime and defence manufacturing ecosystem, the Government of Andhra Pradesh has approved a proposal by Sagar Defence Engineering Private Limited to establish India’s first dedicated Autonomous Maritime Shipyard and Systems Development Centre at Juvvaladinne Fishing Harbour in Bogole Mandal of SPSR Nellore district.

see more..

UAE-based HNIs to fund Rs 1000 Cr in Kerala's startup ecosystem

14 Dec 2025 | 8:01 PM

Thiruvananthapuram, Dec 14 (UNI) Giving a major boost to Kerala’s innovation ecosystem, UAE-based Feeder Fund, spearheaded by the Global Alliance, will provide Rs 1000 crore fund for startups in the state over a period of three years.

see more..